# Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

> **NCT04633187** · PHASE2 · TERMINATED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 9 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** EDP-938
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04633187
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-07
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study was terminated due to a strategic business decision and not due to safety concerns.
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633187, "Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04633187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*